Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy [Phase 2]

View source ↗

Summary

This entry reports on a Phase 2 trial evaluating ibrutinib for mantle cell lymphoma in patients who progressed after bortezomib, with the study status shown as …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED